Wednesday 19 Jan, 2022 09:59 AM
Site map | Locate Us | Login
   Telecom stocks in action after TRAI data    L&T Technology Services Ltd Falls 7.56%, S&P BSE IT Sector index Drops 1.62%    L&T Technology Services Q3 PAT rises 8% Q-o-Q to Rs 250 cr    Vedanta Ltd Spikes 2%    Nandan Denim rises on bonus issue plan    Reliance Jio prepays Rs 30,791 cr spectrum dues    Jubilant Foodworks launches Popeyes in India    Bajaj Finance Q3 PAT surges 85% YoY to Rs 2,125 cr    Tata Elxsi Q3 PAT jumps 43% YoY to Rs 151 cr    Trident Q3 PAT jumps 88% YoY to Rs 211 cr    Dilip Buildcon Ltd leads losers in 'A' group    ICICI Securities Q3 PAT rises 42% YoY to Rs 380 cr    TV18 Broadcast Q3 PAT slides 6% YoY to Rs 200 cr    The Anup Engineering Ltd leads losers in 'B' group    Ramkrishna Forgings Q3 PAT grows 171% to Rs 45 cr, declares 5-for-1 stock split 
Saravan Stocks
       
Hot Pursuit
Scrips, which has significant changes during the market hours.
Sanofi India gains on selling Soframycin, Sofradex biz
26-Nov-21   14:49 Hrs IST

Sanofi Group has decided to enter into a transaction with Encube Ethicals (Encube) for transfer of the Soframycin(R) and Sofradex(R), brands, trademarks and associated technical know-how/manufacturing dossiers (registered IP) to Encube. On fulfilment of this transaction, Encube would have the right to exclusively sell and distribute these products in the territories of India and Sri Lanka.

Sanofi India holds certain assets namely marketing intangibles, customer lists/database, trade channel knowledge/wholesaler lists, vendor/supplier data-base, pharmacovigilance/medical database that are related to this distribution business conducted by Sanofi India (collectively called unregistered IP) and product inventory which will be sold to Encube as part of Asset Sale Agreement, for a consideration of approximately Rs 125 crore, subject to working capital adjustments.

The agreement for sale is proposed to be signed on or after 1 December 2021. The sale is expected to be completed in approximately 3 months from signing the asset purchase agreement.

Soframycin and Sofradex are manufactured (through a third-party manufacturing arrangement) and distributed by Sanofi India. The revenue of the company attributable to these brands represented 2.6% of the total sales of the company for the for FY20 and the business contributed 0.2% of the networth of the company as on 31 December 2020.

Sanofi India's net profit surged 298.64% to Rs 529.80 crore on a 9.88% rise in revenue from operations to Rs 754.50 crore in Q3 September 2021 over Q3 September 2020.

Sanofi India is one of the entities through which Sanofi operates in India. It offers a wide array of medicines for therapy areas such as diabetes, cardiology, thrombosis, central nervous system and anti-histamines. The products manufactured by the company are distributed in India and exported to many developed as well as developing countries.

Powered by Capital Market - Live News

   Attention Investors : Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day........issued in the interest of investors.
   Attention Investors : Prevent unauthorised transactions in your account Update your mobile numbers/email IDs with your stock brokers / Depository Participant. Receive information of your transactions directly from Exchange / Depositories on your mobile / email at the end of the day .... Issued in the interest of Investors.
   Attention Investors : KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
   Attention Investors : No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
Email ID: info@ssplwealth.com       Customers grievances : grievances@ssplwealth.com     Compliance officer : Mr.R Udayakumar , compliance@ssplwealth.com,  Mobile No: 7305522205
Hit Count : 18917810
SEBI Regn.Nos : NSE/BSE-INZ000192638 | CDSL : IN-DP-262-2016  |  MCX : INZ000081736
Member IDs : NSE : 11221 | BSE : 6292 | CDSL : 12045000 | MCX : 12815 | AMFI Regn.No : 2662
Designed , Developed & Content provided by CMOTS INFOTECH.(ISO 9001:2015 certified) © Copyright 2011 All Rights Reserved. Saravana Stocks Pvt. Ltd